News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Apr 27, 2015

Summary Toggle aTyr Pharma Appoints Rare Disease Pioneer Mark Goldberg, M.D., to Board of Directors

Clinician and industry veteran brings experience in enzyme replacement therapies PR Newswire SAN DIEGO SAN DIEGO, April 27, 2015 / PRNewswire / -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases,
Apr 9, 2015

Summary Toggle aTyr Pharma Appoints Marcy Graham as Vice President, Investor Relations and Corporate Communications

PR Newswire SAN DIEGO SAN DIEGO, April 9, 2015 / PRNewswire / -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that it has named Marcy Graham as Vice President, Investor
Apr 6, 2015

Summary Toggle aTyr Pharma Files Registration Statement for Proposed Initial Public Offering

PR Newswire SAN DIEGO and HONG KONG SAN DIEGO and HONG KONG, April 6, 2015 / PRNewswire / -- aTyr Pharma, Inc. ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced that it has filed a
Feb 18, 2015

Summary Toggle aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris™ in FSHD

PR Newswire SAN DIEGO SAN DIEGO, Feb. 18, 2015 / PRNewswire / -- aTyr Pharma, Inc. ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today the European Commission (EC) has granted orphan drug
Jan 28, 2015

Summary Toggle aTyr Announces First FSHD Patient Study of Resolaris™

First Physiocrine-Based Therapeutic Administered to Patients PR Newswire SAN DIEGO SAN DIEGO, Jan. 28, 2015 / PRNewswire / -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today
Nov 3, 2014

Summary Toggle aTyr Pharma Appoints Fred Ramsdell, Ph.D., as Vice President, Immunology

- Industry Veteran Established Immunology Research Programs at NovoNordisk, ZymoGenetics - Discovered Foxp3 Gene Critical for Regulating Immune Function PR Newswire SAN DIEGO and HONG KONG SAN DIEGO and HONG KONG, Nov. 3, 2014 / PRNewswire / -- aTyr Pharma ("aTyr"), an innovative rare
Oct 22, 2014

Summary Toggle aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research

Architect of Novel Translational Rare Disease Programs at NIH Adds Depth to Existing Team of Rare Disease Experts PR Newswire SAN DIEGO and HONG KONG SAN DIEGO and HONG KONG, Oct. 22, 2014 / PRNewswire / -- aTyr Pharma ("aTyr"), an innovative rare disease therapeutics enterprise, announced
Jul 17, 2014

Summary Toggle aTyr, The Hong Kong University of Science and Technology, The Scripps Research Institute and Stanford University Join in the Discovery of a New Class of Human Proteins

Publication in Science Unveils Novel, Diverse and Separate Biological Functions That Can Be Harnessed Therapeutically to Mediate a Wide Range of Human Disease PR Newswire SAN DIEGO and HONG KONG SAN DIEGO and HONG KONG, July 17, 2014 / PRNewswire / -- aTyr Pharma, an innovative rare disease